

## STUDY REPORT

STUDY No.

190909/ NNB/ PC

## STUDY TITLE

## ACUTE ORAL (GAVAGE) TOXICITY OF L-3-AMINOISOBUTYRIC ACID IN FEMALE SPRAGUE DAWLEY RATS

Sponsor's name and Address

**Facility Address** 

NNB Nutrition China Room 2009, Suning Huigu Building 118, Morya House, Andheri West, #E8-2, No 268 Jiqingmen Street, Nanjing, 210017, China

Vedic Lifesciences Pvt. Ltd. Mumbai, Maharashtra India



## Study Report Approval

|  | ,                                   |
|--|-------------------------------------|
| On Behalf of Vedic Lifesciences Pvt. L | .td.                                |
| Study Monitor- Dr Dipti Aswalkar       | December 27,2019  Date/Month/Year   |
| QAU- Anil Yadav                        | December 27, 2019.  Date/Month/Year |
| On behalf of Sponsor                   |                                     |
| Mina Wang                              | . Date/Month/Year                   |



## GOOD LABORATORY PRACTICE COMPLIANCE STATEMENT

This study was conducted in accordance with OECD Principles of Good Laboratory Practice (GLP), document no. ENV/MC/CHEM (98)17 (as revised in 1997) and adopted by the decision of the OECD Council [C(97)186/Final]. This study was performed in accordance with the Standard Operating Procedures and signed Study Plan.

There were no circumstances that might have affected the quality or integrity of the study.

No circumstances in the study have been left unreported which might have influence on the quality or integrity of the study.

This is also to certify that the results presented in this report are complete, true and accurate reflection of the raw data obtained during the conduct of the study and I, hereby accept the responsibility for the validity of the data.

Aladar

December 27, 2019.
Date/Month/Year

Mr. Anil Yadav

**Quality Assurance** 



## TABLE OF CONTENTS

| GOOD LABORATORY PRACTICE COMPLIANCE STATEMENT                                     | 3  |
|---|----|
| 1.LIST OF ABBREVIATIONS   | 6  |
| 2.SUMMARY   |    |
| 3.OBJECTIVE   | 9  |
| 4.TEST GUIDELINE  | 9  |
| 5.SAFETY PRECAUTIONS  |    |
| 6.AMENDMENT AND DEVIATION PROCEDURES  |    |
| 7.STUDY INFORMATION   | 9  |
| 8.STUDY SCHEDULE  | 9  |
| 9.TEST ITEM INFORMATION   | 10 |
| 9.1. VEHICLE AND JUSTIFICATION  |    |
| 9.2. DOSE FORMULATIONS  | 11 |
| 10.TEST SYSTEM DETAILS  | 11 |
| 11.ANIMAL HUSBANDRY   |    |
| 12.EXPERIMENTAL DESIGN  |    |
| 12.1. DOSE SELECTION  | 13 |
| 12.2. ROUTE OF ADMINISTRATION   | 13 |
| 12.4. DOSE FORMULATION PREPARATION  |    |
| 12.5. TREATMENT   | 14 |
| 13.IN-LIFE OBSERVATIONS   | 15 |
| 13.1. MORBIDITY/MORTALITY   | 15 |
| 13.2. CLINICAL SIGNS OF TOXICITY  |    |
| 13.3. BODY WEIGHT   | 15 |
| 13.4. NECROPSY  | 15 |
| 13.5. STATISTICAL ANALYSIS  | 15 |
| 14.RESULTS  | 16 |
| 14.1. CLINICAL SIGNS, MORBIDITY/MORTALITY   | 16 |
| 14.2. BODY WEIGHT   | 16 |
| 14.3. GROSS PATHOLOGY15.CONCLUSION  | 16 |
|   |    |
| 16.ARCHIVING  |    |
| TABLE 1 - SUMMARY OF CLINICAL SIGN ORSERVATION AND MORRIDITY/MORTALI              |    |
| LEADLE LE ROUNDINER L'OF CLUNICAL SICIN CHINEVA LIUN AND AND MIDDENNITO MANDENT L |    |



| TABLE 2 - INDIVIDUAL ANIMAL BODY WEIGHT (G) AND DOSE ADMINISTRATION I | DETAILS |
|---|---------|
|   | 20      |
| TABLE 3 - INDIVIDUAL ANIMAL GROSS PATHOLOGICAL FINDINGS               | 21      |
| ANNEXURE 1 - AOT425 STATPGM (VERSION: 1.0) TEST RESULTS AND RECOMMEND | ATIONS  |
|   | 22      |
| ANNEXURE 2- DOSE PROGRESSIONS - OECD TG 425                           | 23      |
| ANNEXURE 3 - CERTIFICATE OF ANALYSIS L-3-AMINOISOBUTYRIC ACID         | 24      |
| ANNEXURE 4 - CERTIFICATE OF ANALYSIS OF FEED                          | 25      |
| ANNEXURE 5 - CERTIFICATE OF ANALYSIS OF WATER                         | 26      |
| ANNEXURE 6 - CERTIFICATE OF ANALYSIS OF BEDDING MATERIAL              | 31      |



## 1. LIST OF ABBREVIATIONS

°C Degree Celsius

B. wt Body weight

Conc. Concentration

CoA Certificate of Analysis

F Female(s)

G Gram (s)

GHS Globally Harmonised System

H Hour/s

Kg Kilogram/s

LD<sub>50</sub> Lethal Dose 50%

Mg Milligram

Min Minute/s

mL Milliliter

RT Room Temperature

RH Relative Humidity

SOP Standard Operating Procedure

UDP UP and Down Procedure



## 2. SUMMARY

Acute oral toxicity study was conducted to evaluate the toxicity of L-3-Aminoisobutyric Acid upon a single oral administration to Sprague Dawley Rats followed by observation for 14 days. The study was also intended to identify the LD<sub>50</sub> of L-3-Aminoisobutyric Acid. The method followed was as per the OECD Guidelines for Testing of Chemicals, Number 425.

L-3-Aminoisobutyric Acid was initially tested at a dose of 175 mg/kg b.wt. in Step 1 with one female rat, slope 4 was followed for this study. Based on the survival pattern of the previously dosed animal after 48 hours, further doses were decided as per OECD TG 425 StatPgm.

The experiment consisted of seven steps with one female rat at each step treated with L-3-Aminoisobutyric Acid by oral gavage administration at a dose of 175 mg/kg b.wt. for Step 1, 310 mg/kg b.wt. for Step 2, 550 mg/kg b.wt. for Step 3, 980 mg/kg b.wt. for Step 4; and 2000 mg/kg b.wt. for Step 5, 6 & 7. The test item was formulated in vehicle (distilled water) at a concentration of 17.5, 31.0, 55.0, 98.0 mg/mL for step 1, 2, 3 & 4, respectively; and 200 mg/mL for step 5, 6 & 7 respectively. The test item was administered at a dose volume of 10 mL/kg body weight.

The animals were observed twice daily throughout the treatment period for mortality and moribundity. The animals were also observed for clinical signs approximately at 30 minutes, 1, 2, 3 and 4 hours on day 0 post dosing; and twice daily during the experimental i.e. day 1 to day 14 for each step. The body weight was recorded on day 0 (prior to dosing), day 7 and day 14. At the end of experimental period (day 14), the animals were euthanized and subjected to a detailed gross pathological examination.

No treatment related clinical signs, mortality and moribundity was observed throughout the experiment period.

All the animals gained body weight over the course of the study as compared to day 0.

There were no gross pathological changes observed in any of the treated animals.





## Conclusion

Based on the results of this study, the median lethal dose (LD<sub>50</sub>) of L-3-Aminoisobutyric Acid after single oral administration to female Sprague Dawley Rats, observed over a period of 14 days is greater than 2000 mg/kg body weight, and the test item is classified as 'Category 5' based on The Globally Harmonized System of Classification and Labelling of Chemicals (GHS).



#### 3. OBJECTIVE

The objective of this study was to assess the toxicity of L-3-Aminoisobutyric Acid following single oral (gavage) administration to female Sprague Dawley rats.

## TEST GUIDELINE

The study procedures described in the study report meet the requirements of the following guideline:

OECD Guidelines for Testing of Chemicals Section 4: Health Effects: No. 425, Acute Oral Toxicity - Up-and-Down-Procedure (UDP); Adopted: 3rd October 2008.

#### 5. SAFETY PRECAUTIONS

Safety measures were adopted to ensure adequate personal health and safety. Aprons, gloves, cap and face mask were used in addition to protective laboratory wares and rubber slipper to avoid inhalation or skin contact with the test item.

## AMENDMENT AND DEVIATION PROCEDURES

There was no amendment or deviation to the study plan generated.

#### 7. STUDY INFORMATION

Study title

Acute Oral Toxicity Study (Up and Down Procedure) of

L-3-Aminoisobutyric Acid in Sprague Dawley Rats.

Study number

: 190909/ NNB/ PC

Monitoring Scientist

Dr. Dipti Aswalkar :

## STUDY SCHEDULE

Study Initiation Date

: 17 October 2019

Experimental Start Date

: 17 October 2019

Acclimatization period

Step-1: 17 October 2019 to 22 October 2019

Step-2 : 17 October 2019 to 25 October 2019

Step-3 : 17 October 2019 to 28 October 2019

Vedic Lifesciences Pvt. Ltd.

Confidential

Page 9 of 31



 Step-4
 : 17 October 2019 to 01 November 2019

 Step-5
 : 17 October 2019 to 04 November 2019

 Step-6
 : 17 October 2019 to 07 November 2019

 Step-7
 : 17 October 2019 to 11 November 2019

Treatment Dates Step-1: 23 October 2019

 Step-2
 : 26 October 2019

 Step-3
 : 29 October 2019

 Step-4
 : 02 November 2019

 Step-5
 : 05 November 2019

 Step-6
 : 08 November 2019

 Step-7
 : 12 November 2019

Necropsy Step-1: 06 November 2019

 Step-2
 : 09 November 2019

 Step-3
 : 12 November 2019

 Step-4
 : 16 November 2019

 Step-5
 : 19 November 2019

 Step-6
 : 22 November 2019

 Step-7
 : 26 November 2019

Experimental Completion Date : 26 November 2019
Draft Report Submission Date : 11 December 2019
Study Completion date : 27 December 2019

## 9. TEST ITEM INFORMATION

The details of the test item information given in the following section were as provided by the sponsor (Refer Annexure 3 -CoA)

Test Item name : L-3-Aminoisobutyric Acid

Appearance : White crystalline powder

Batch Number : 20190801

Assay (Dry Basis) : 99.64%

Manufacture date : August 17, 2019

Vedic Lifesciences Pvt. Ltd. Confidential Page 10 of 31



from

container.

Assay (Dry Basis)

: 99.64%

Manufacture date

: August 17, 2019

Expiry date

: August 16, 2021

Stored

Storage conditions

in

moisture and direct sunlight (ambient temperature).

sealed

Note: The identity, stability and composition of the test item were the responsibility of the Sponsor. No analysis of the test item was conducted at Test facility to confirm it.

tightly

## VEHICLE AND JUSTIFICATION

Based on the solubility and syringibility test distilled water was selected as a vehicle.

## 9.2. DOSE FORMULATIONS

The dose formulations were prepared shortly before each dosing for all the steps.

The required quantity of test item (175.01 mg for Step 1, 310.09 mg for Step 2, 550.05 mg for Step 3, 980.03 mg for Step 4, 2000.02 mg for Step 5, 2000.05 mg for Step 6 and 2000.03 mg for Step 7) was received from Test Item Control Office and was transferred to a mortar and triturated with pestle. 3-4 mL of the vehicle was added to the mortar and again triturated. This was then transferred to a calibrated volumetric flask. 1-2 mL of vehicle was used twice to rinse the mortar and pestle. Sufficient quantity of vehicle was then added to make up to the final volume of 10 mL. This was then transferred back to the beaker and mixed properly.

#### 10. TEST SYSTEM DETAILS

Animal species

: Rats

Strain

Sprague Dawley

Justification for

selection of species

: Recommended by the guideline

Sex

: Female (nulliparous and non-pregnant)

Number of animals per : 1 animal per step.

step

Vedic Lifesciences Pvt. Ltd.

Confidential

Page 11 of 31





Age of animals

: 9 - 12 weeks

Body weight range

: 166.45 to 195.61 g at the time of dosing (weight variation was within an interval of ± 20% of mean weight of previously dosed animals)

Total No. of Animals

: 15 animals were received for the study and 7 animals were used for the treatment. Unused animals were returned to the animal house.

Identification

: The animals were marked (towards the tip of tail) with the temporary animal numbers at start of acclimatization. The animals were marked with permanent animal numbers (towards the base of tail) with different colour indelible marker pen before the start of test item administration. Each cage card was having details like Study No., Study Code, Species & Strain, Step, Dose, Sex, Animal No., Cage No.

### 11. ANIMAL HUSBANDRY

- a). Acclimatization: Animals were acclimatized for minimum 5 days prior to the treatment. At the time of receipt and before selection for dosing, animals were subjected to health assessment and only animals without any visible sign of illness were used for the study.
- b). Environmental Conditions: Animals were housed with adequate fresh air supply (12-15 air changes per hour), temperature of 19.8 to 23.8 °C, relative humidity range of 41 to 66 % and photo period of 12 h light and 12 h dark. The temperature and relative humidity was recorded once daily.
- c). Housing: One animal per cage was housed in polycarbonate cages (size: 410 X 282 X 150 mm as length, width and height respectively) with stainless steel top grills having facilities for holding feed and water. Enrichment was provided in the individual cage.
- d). Bedding: Sterilized Comfort (Corn Cob), Batch number: 015 was used as bedding material. Chemical and microbial analysis reports were archived along with study file.
- e). Feed: Rat/Mice Pellet feed (Batch Number: 023) was provided ad libitum Proximate, contaminant and microbial analysis report were maintained along the study file.



- f). Water: Reverse osmosis water was provided ad libitum throughout the study period.
  The results of analysis of water samples were maintained along the study file.
- g). Animal Selection: The animals were manually selected in such a way that the weight variation was within  $\pm$  20 % of previously dosed animals. To enable this, the animals with highest body weight were selected at each step.

## 12. EXPERIMENTAL DESIGN

| Step     | Dose             | No. of Animals | Animal Number |
|----------|------------------|----------------|---------------|
| Step - 1 | 175 mg/Kg b.wt.  | 1              | 001           |
| Step - 2 | 310 mg/Kg b.wt.  | 1              | 002           |
| Step - 3 | 550 mg/Kg b.wt.  | 1              | 003           |
| Step - 4 | 980 mg/Kg b.wt.  | 1              | 004           |
| Step - 5 | 2000 mg/Kg b.wt. | 1              | . 005         |
| Step - 6 | 2000 mg/Kg b.wt. | 1              | 006           |
| Step - 7 | 2000 mg/Kg b.wt. | 1              | 007           |

## 12.1. DOSE SELECTION

Since there is no information about toxicity or LD<sub>50</sub> of test item, the starting dose of 175 mg/kg/b.wt was selected as per guidelines' recommendation. As per the sponsor suggestion Slope 4 was followed for this study. Based on the mortality or survival pattern of the previously dosed animal after 48 hours, further doses were decided as per OECD TG 425 StatPgm.

## 12.2. 12.2. ROUTE OF ADMINISTRATION

Test item was administered by oral route and it was selected based on the guideline requirement.

## 12.3. JUSTIFICATION FOR CHOICE OF VEHICLE

Based on the solubility and syringibility test distilled water was selected as a vehicle.



## 12.4. DOSE FORMULATION PREPARATION

The test item was formulated in distilled water. The dose formulations were prepared shortly before each dosing for all the steps. The required quantity of test item (175.01 mg for Step 1, 310.09 mg for Step 2, 550.05 mg for Step 3, 980.03 mg for Step 4, 2000.02 mg for Step 5, 2000.05 mg for Step 6 and 2000.03 mg for Step 7) was received from Test Item Control Office and was transferred to a mortar and triturated with pestle. 3-4 mL of the vehicle was added to the mortar and again triturated. This was then transferred to a calibrated volumetric flask. 1-2 mL of vehicle was used twice to rinse the mortar and pestle. Sufficient quantity of vehicle was then added to make up to the final volume of 10 mL. This was then transferred back to the beaker and mixed properly.

#### 12.5. TREATMENT

The animals received a single dose of the test item based on their body weight by oral gavage administration after being fasted overnight (approximately 15 hours), but with free access to water. Food was supplied approximately 3 hours post treatment. The dose administered to individual rat was adjusted according to its body weight recorded prior to dosing. The dose volume was 10 mL/kg body weight.

**Note**: Homogeneity of the test item in the vehicle was maintained during administration using a magnetic stirrer. The left-over formulations were disposed as per in house Standard Operating Procedure.



## 13. IN-LIFE OBSERVATIONS

The following observations were carried out during the study.

## 13.1. MORBIDITY/MORTALITY

All animals were observed for morbidity/mortality twice daily during the study period (once on holidays).

## 13.2. CLINICAL SIGNS OF TOXICITY

Animals were observed for clinical signs of toxicity, at least once daily during acclimatization, at 30 min and 1, 2, 3 and 4 hrs post-dosing on day 0; and thereafter twice daily for the 14-day observation period (once on holidays and day of sacrifice for each step). Animals were observed for changes in skin, fur, eyes and mucous membranes and respiratory, circulatory and nervous system.

## 13.3. BODY WEIGHT

Individual animal body weights were recorded on the day of animal receipt, selection and on the day of dosing before administration of test item (day 0) and on Day 7 and 14. Percent body weight changes were calculated.

#### 13.4. NECROPSY

At the end of the observation period, all the surviving animals were sacrificed using carbon dioxide asphyxiation in euthanasia chamber and subjected to gross pathological evaluation.

## 13.5. STATISTICAL ANALYSIS

AOT425 StatPgm was used to select the doses, stopping criterion and estimation of LD50.



## 14. RESULTS

## 14.1. CLINICAL SIGNS, MORBIDITY/MORTALITY

No clinical signs, mortality and moribundity was observed in any of the test item treated animals (Table 1).

## 14.2. BODY WEIGHT

All the animals gained body weight over the course of the study in all the steps as compared to day 0 (Refer Table 2).

### 14.3. GROSS PATHOLOGY

No gross pathological changes were observed in any of the treated animals. (Table 3)

#### 15. CONCLUSION

Based on the results of this study, the median lethal dose (LD<sub>50</sub>) of L-3-Aminoisobutyric Acid after single oral administration to female Sprague Dawley Rats, observed over a period of 14 days is greater 2000 mg/kg body weight and it is classified as 'Category 5' based on The Globally Harmonized System of Classification and Labelling of Chemicals (GHS).

## 16. ARCHIVING

The study plan, raw data, slides and study report will be maintained in the archives of Vedic Lifesciences Pvt Ltd. for 9 years from the date of completion of the study. The soft copies of the study plan, study report and compiled data will be copied to compact disc and will be archived for 9 years from the date of completion of the study. A sample of the test item will be maintained in the archives of Vedic Lifesciences Pvt Ltd. till the expiry date of the test item. At the end of the archiving period, the sponsor's instructions will be sought either to extend the archiving period or to return the archived material to the sponsor or for the disposal.



## 17. REFERENCES

- Compendium of CPCSEA 2018, Ministry of Environment, Forests and Climate Change, Government of India.
- b. Guide 2011 Guide for the Care and Use of Laboratory Animals, Institute of Laboratory Animal Resources. Commission on Life Sciences. National Research Council. National Academy Press. Washington, D.C. 2011.
- c. Guidance Document on the Recognition, Assessment and Use of Clinical signs as humane endpoints for Experimental Animals used in Safety Evaluation. ENV/JM/MONO (2000)7. OECD, December, 2000.
- d. OECD Guidelines for Testing of Chemicals No. 425, "Acute Oral Toxicity Up and Down Procedure", adopted 03rd October 2008.
- United Nations Economics Commission for Europe: Globally Harmonized System of Classification and Labelling of Chemicals (GHS); ST/SG/AC.10/30/Rev.7, 2017.



# TABLE 1 - SUMMARY OF CLINICAL SIGN OBSERVATION AND MORBIDITY/MORTALITY

| Step - 1 | 1  |     |     |      |   |   |   | D   | os | e: | 17 | 5 1 | mg | /k  | g l | Bo  | dy | w   | ei | gh | t |     |    |   |   | 5   | Sex | (: ] | Fei | ma | ale |    |    |
|----------|----|-----|-----|------|---|---|---|-----|----|----|----|-----|----|-----|-----|-----|----|-----|----|----|---|-----|----|---|---|-----|-----|------|-----|----|-----|----|----|
|          |    |     |     |      |   |   |   |     |    |    |    |     |    |     |     | Da  | y  |     |    |    |   |     |    |   |   |     |     |      |     |    |     |    |    |
| Animal   |    |     | (   | )    |   |   |   | 1   |    | 2  |    | 3   | ,  | 4   | :   | 5   |    | 6   |    | 7  |   | 8   | !  | 9 | 1 | 0   | 1   | 1    | 1   | 2  | 1   | 3  | 14 |
| No.      |    | ŀ   | iou | r(s) | ) |   |   | Ī., |    |    | -  | Ī., | -  | Ī., |     | Ī., | -  | Ī., | Ŀ  | T  | 1 | Ī., | Ī. |   | Ŀ | Ī., | Ī.  | Ī.,  |     |    | L   | Ι  | -  |
|          | PD | 0.5 | 1   | 2    | 3 | 4 | 1 | ш   | 1  | Ш  | 1  | 111 | 1  | 11  | 1   | ш   | 1  | 11  | 1  | п  | 1 | Ш   | 1  | ш | 1 | ш   | 1   | Ш    | 1   | 11 | I   | 11 | I  |
| 001      | 0  | 0   | 0   | 0    | 0 | 0 | 0 | 0   | 0  | 0  | 0  | 0   | 0  | -   | 0   | 0   | 0  | 0   | 0  | 0  | 0 | 0   | 0  | 0 | 0 | -   | 0   | -    | 0   | 0  | 0   | 0  | 0  |

| Step - 2 | 2  |     |     |      |   |   |   | D | os | e:  | 31 | 0 1 | ng | /k | g l | Bo | dy | w | ei | gh  | t |     |   |     |   | 5 | Sex | <b>:</b> ] | Fe | ma  | ıle |     |    |
|----------|----|-----|-----|------|---|---|---|---|----|-----|----|-----|----|----|-----|----|----|---|----|-----|---|-----|---|-----|---|---|-----|------------|----|-----|-----|-----|----|
|          |    |     |     |      |   |   |   |   |    |     |    |     |    |    |     | Da | y  |   |    |     |   |     |   |     |   |   |     |            |    |     |     |     |    |
| Animal   |    |     | (   | )    |   |   |   | 1 |    | 2   |    | 3   | Ţ. | 4  | 1   | 5  |    | 6 |    | 7   |   | 8   | 1 | 9   | 1 | 0 | 1   | 1          | 1  | 2   | 1   | 3   | 14 |
| No.      |    | 1   | iou | r(s) |   |   |   |   | Ţ  |     | Ţ  |     |    |    |     |    |    |   | Ι. | Ī., |   |     |   |     |   |   |     |            | -  |     |     | Ī., |    |
|          | PD | 0.5 | 1   | 2    | 3 | 4 | 1 | ш | 1  | 111 | 1  | ш   | 1  | ш  | 1   | ш  | 1  | ш | 1  | II  | 1 | 111 | 1 | 111 | 1 | ш | 1   | 11         | 1  | 111 | 1   | 11  | 1  |
| 002      | 0  | 0   | 0   | 0    | 0 | 0 | 0 | - | 0  | 0   | 0  | 0   | 0  | 0  | 0   | 0  | 0  | 0 | 0  | -   | 0 | -   | 0 | 0   | 0 | 0 | 0   | 0          | 0  | 0   | 0   | 0   | 0  |

| Step - 3 | 3  |     |     |      |   |   |   | D  | os | e: | 55 | 0 1 | ng | /k | g] | Bo | dy | w   | ei | gh  | t |    |   |     |   | 5 | Sex | : <u>]</u> | Fei | ma | ale |     |    |
|----------|----|-----|-----|------|---|---|---|----|----|----|----|-----|----|----|----|----|----|-----|----|-----|---|----|---|-----|---|---|-----|------------|-----|----|-----|-----|----|
|          |    |     |     |      |   |   |   |    |    |    |    |     |    |    |    | Da | y  |     |    |     |   |    |   |     |   |   |     |            |     |    |     |     |    |
| Animal   |    |     | (   | )    |   |   |   | 1  | :  | 2  | :  | 3   |    | 4  | :  | 5  |    | 6   | T  | 7   |   | 8  | ! | 9   | 1 | 0 | 1   | 1          | 1   | 2  | 1   | 13  | 14 |
| No.      |    | ŀ   | iou | r(s) |   |   | Ţ |    |    |    | Ţ  |     | Ţ  |    | Ţ  |    | Ţ  | Ī., | Ţ  | Ī., | Ţ |    | Ţ | Ī., |   |   | Ţ   |            | Ţ   |    | Ţ   | Ī., | Ţ  |
|          | PD | 0.5 | 1   | 2    | 3 | 4 | 1 | 11 | 1  | ш  | 1  | ш   | 1  | ш  | I  | 11 | 1  | ш   | ı  | ш   | 1 | 11 | 1 | ш   | ı | ш | I   | ш          | 1   | ш  | 1   | п   | 1  |
| 003      | 0  | 0   | 0   | 0    | 0 | 0 | 0 | 0  | 0  | 0  | 0  | 0   | 0  | -  | 0  | -  | 0  | 0   | 0  | 0   | 0 | 0  | 0 | 0   | 0 | 0 | 0   | 0          | 0   | -  | 0   | 0   | 0  |

| Step - | 4  |     |     |      |   |   |   | D  | os | e: | 98 | 0 1 | mg | /k | g ] | Во | dy | w   | ei | gh  | t |     |   |   |   | 5 | Sex | (: J | Fe | ma | ıle |    |    |
|--------|----|-----|-----|------|---|---|---|----|----|----|----|-----|----|----|-----|----|----|-----|----|-----|---|-----|---|---|---|---|-----|------|----|----|-----|----|----|
|        |    |     |     |      |   |   |   |    |    |    |    |     |    |    |     | Da | y  |     |    |     |   |     |   |   |   |   |     |      |    |    |     |    |    |
| Animal |    |     | (   | )    |   |   |   | 1  | 1  | 2  | :  | 3   | ,  | 4  | :   | 5  |    | 6   | 1  | 7   |   | 8   | Ţ | 9 | 1 | 0 | 1   | 1    | 1  | 2  | 1   | 13 | 14 |
| No.    |    | ŀ   | ıou | r(s) |   |   | Ţ |    | Ţ  |    | Ţ  |     | Ţ  |    | Ţ   |    | Ţ  |     | Ţ  | T., | Ţ |     |   |   | Ţ |   |     |      | Ţ  |    | Į,  |    | -  |
|        | PD | 0.5 | 1   | 2    | 3 | 4 | 1 | 11 | 1  | ш  | 1  | ш   | 1  | ш  | 1   | 11 | 1  | 111 | 1  | ш   | 1 | 111 | 1 | ш | 1 | ш | 1   | П    | 1  | ш  | 1   | 11 | 1  |
| 004    | 0  | 0   | 0   | 0    | 0 | 0 | 0 | -  | 0  | 0  | 0  | 0   | 0  | 0  | 0   | 0  | 0  | 0   | 0  | 0   | 0 | -   | 0 | 0 | 0 | 0 | 0   | 0    | 0  | 0  | 0   | 0  | 0  |

PD: Pre dose; I: 1st observation; II: 2nd observation; 0: Normal; -: Not observed; 0.5 hours: 30 minutes

## **TABLE 1 Continued**

| Step - : | 5  |     |     |      |   |   |     | D   | os | e: | 20 | 00 | n | ıg/ | kg | В  | od | y  | we | ig  | ht |    |   |    |   | 5 | Sex | <b>:</b> ] | Fe | ma | ale |    |    |
|----------|----|-----|-----|------|---|---|-----|-----|----|----|----|----|---|-----|----|----|----|----|----|-----|----|----|---|----|---|---|-----|------------|----|----|-----|----|----|
|          |    |     |     |      |   |   |     |     |    |    |    |    |   |     |    | Da | y  |    |    |     |    |    |   |    |   |   |     |            |    |    |     |    |    |
| Animal   |    |     | (   | )    |   |   |     | 1   | :  | 2  |    | 3  |   | 4   | :  | 5  | -  | 6  | 1  | 7   |    | 8  | 9 | 9  | 1 | 0 | 1   | 1          | 1  | 2  | 1   | 3  | 14 |
| No.      |    | 1   | ıou | r(s) | , |   | Ţ   | Ī., |    |    | Ţ  |    |   | Ī., | Ţ  |    | Ţ  |    | Ţ  | T., | Ţ  |    | Ţ |    |   |   |     |            | Ţ  |    | Ţ   |    | T. |
|          | PD | 0.5 | 1   | 2    | 3 | 4 | l I | 111 | 1  | 11 | 1  | ш  | 1 | 11  | 1  | 11 | 1  | 11 | 1  | II  | 1  | 11 | 1 | 11 | 1 | ш | 1   | 11         | I  | 11 | 1   | 11 | 1  |
| 005      | 0  | 0   | 0   | 0    | 0 | 0 | 0   | 0   | 0  | 0  | 0  | 0  | 0 | 0   | 0  | -  | 0  | 0  | 0  | 0   | 0  | 0  | 0 | 0  | 0 | 0 | 0   | -          | 0  | -  | 0   | 0  | 0  |

| Step - | 6  |     |     |      |   |   |   | D  | os | e:  | 20 | 00 | m | ıg/ | kg | B  | od | y١ | we | igl | ht |    |   |    |   | 5  | Sex | ::1 | Fei | ma | ale |    |    |
|--------|----|-----|-----|------|---|---|---|----|----|-----|----|----|---|-----|----|----|----|----|----|-----|----|----|---|----|---|----|-----|-----|-----|----|-----|----|----|
|        |    |     |     |      |   |   |   |    |    |     |    |    |   |     | 8  | Da | y  |    |    |     |    |    |   |    |   |    |     |     |     |    |     |    |    |
| Animal |    |     | (   | )    |   |   |   | 1  | 1  | 2   | :  | 3  |   | 4   | :  | 5  |    | 6  |    | 7   |    | 8  | ! | 9  | 1 | 0  | 1   | 1   | 1   | 2  | 1   | 13 | 14 |
| No.    |    | ŀ   | iou | r(s) |   |   | Ţ |    |    |     |    |    | Ţ |     | ,  |    | Ţ  |    | Ţ  |     |    |    | Ţ |    | Ţ |    |     |     | Ţ   |    | Ţ   |    |    |
|        | PD | 0.5 | 1   | 2    | 3 | 4 | 1 | 11 | 1  | 111 | 1  | 11 | 1 | 11  | 1  | 11 | 1  | 11 | 1  | 11  | 1  | 11 | 1 | 11 | 1 | 11 | 1   | 11  | 1   | 11 | 1   | п  | 1  |
| 006    | 0  | 0   | 0   | 0    | 0 | 0 | 0 | 0  | 0  | -   | 0  | 0  | 0 | 0   | 0  | 0  | 0  | 0  | 0  | 0   | 0  | -  | 0 | -  | 0 | 0  | 0   | 0   | 0   | 0  | 0   | 0  | 0  |

| Step - ' | 7  |     |    |      |   |   |    | D | os | e: | 20 | 00  | m | ıg/ | kg | B  | od | уv | we | igl | ht |   |   |   |   | 5   | Sex | <b>:</b> ] | Fe | ma  | ale |   |    |
|----------|----|-----|----|------|---|---|----|---|----|----|----|-----|---|-----|----|----|----|----|----|-----|----|---|---|---|---|-----|-----|------------|----|-----|-----|---|----|
|          |    |     |    |      |   |   |    |   |    |    |    |     |   |     |    | Da | y  |    |    |     |    |   |   |   |   |     |     |            |    |     |     |   |    |
| Animal   |    |     | (  | )    |   |   |    | 1 |    | 2  |    | 3   |   | 4   |    | 5  |    | 6  | -  | 7   |    | 8 |   | 9 | 1 | 0   | 1   | 1          | 1  | 2   | 1   | 3 | 14 |
| No.      |    | ŀ   | ou | r(s) | 1 |   | Ţ. |   |    |    |    |     |   |     |    |    | Ţ  |    |    | I., | Ţ  |   | _ |   |   | Ī., | Ţ   |            |    | Ī., |     |   |    |
|          | PD | 0.5 | 1  | 2    | 3 | 4 | 1  | ш | 1  | ш  | 1  | 111 | 1 | ш   | 1  | ш  | 1  | ш  | 1  | ш   | 1  | ш | 1 | ш | 1 | ш   | 1   | ш          | 1  | 111 | 1   | п | 1  |
| 007      | 0  | 0   | 0  | 0    | 0 | 0 | 0  | 0 | 0  | 0  | 0  | 0   | 0 | -   | 0  | -  | 0  | 0  | 0  | 0   | 0  | 0 | 0 | 0 | 0 | 0   | 0   | 0          | 0  | -   | 0   | 0 | 0  |

PD: Pre dose; I: 1st observation; II: 2nd observation; 0: Normal; -: Not observed; 0.5 hours: 30 minutes



# TABLE 2 - INDIVIDUAL ANIMAL BODY WEIGHT (G) AND DOSE ADMINISTRATION DETAILS

| Step &           | Animal | Body<br>weight (g) | Dose           | Body w | eight (g) |            | ge in Body<br>ight |
|------------------|--------|--------------------|----------------|--------|-----------|------------|--------------------|
| (mg/kg<br>b.wt.) | No.    | Day 0              | Volume<br>(mL) | Day 7  | Day 14    | Day<br>0-7 | Day<br>0 -14       |
| Step 1<br>& 175  | 001    | 195.61             | 2.0            | 206.61 | 212.49    | 5.62       | 8.63               |
| Step 2<br>& 310  | 002    | 195.41             | 2.0            | 209.73 | 226.21    | 7.33       | 15.71              |
| Step 3<br>& 550  | 003    | 193.23             | 1.9            | 209.80 | 225.94    | 8.58       | 16.93              |
| Step 4<br>& 980  | 004    | 187.92             | 1.9            | 203.01 | 221.09    | 8.03       | 17.65              |
| Step 5<br>& 2000 | 005    | 167.73             | 1.7            | 178.91 | 185.73    | 6.67       | 10.73              |
| Step 6<br>& 2000 | 006    | 166.45             | 1.7            | 182.34 | 200.02    | 9.55       | 20.17              |
| Step 7<br>& 2000 | 007    | 169.94             | 1.7            | 188.09 | 195.93    | 10.68      | 15.29              |



## TABLE 3 - INDIVIDUAL ANIMAL GROSS PATHOLOGICAL FINDINGS

| Step &<br>Dose (mg/kg<br>b.wt.) | Animal<br>Number | Fate of animals | External | Internal |
|---------------------------------|------------------|-----------------|----------|----------|
| Step 1 & 175                    | 001              | TS              | NAD      | NAD      |
| Step 2 & 310                    | 002              | TS              | NAD      | NAD      |
| Step 3 & 550                    | 003              | TS              | NAD      | NAD      |
| Step 4 & 980                    | 004              | TS              | NAD      | NAD      |
| Step 5 & 2000                   | 005              | TS              | NAD      | NAD      |
| Step 6 & 2000                   | 006              | TS              | NAD      | NAD      |
| Step 7 & 2000                   | 007              | TS              | NAD      | NAD      |

TS: Terminal Sacrifice; NAD = No Abnormality Detected



# ANNEXURE 1 - AOT425 STATPGM (VERSION: 1.0) TEST RESULTS AND RECOMMENDATIONS

Acute Oral Toxicity (OECD Test Guideline 425) Statistical Program

Date/Time: 29 November 2019, 17:17:13

Data file name: work.dat

Last modified: 29/11/2019 17:17:13

Test type: Main Test Limit dose (mg/kg): 2000

Assumed LD<sub>50</sub> (mg/kg): Default Assumed sigma (mg/kg): 0.249999

Recommended dose progression: 2000, 980, 550, 310, 175, 98, 55, 31, 17.5, 9.8, 5.5, 3.1, 1.75

## DATA:

| Test<br>Seq. | Animal<br>ID | Dose<br>(mg/kg) | Short-term<br>Result | Long-term<br>Result |
|--------------|--------------|-----------------|----------------------|---------------------|
| 1            | 001          | 175             | 0                    | 0                   |
| 2            | 002          | 310             | O                    | O                   |
| 3            | 003          | 550             | O                    | O                   |
| 4            | 004          | 980             | O                    | O                   |
| 5            | 005          | 2000            | O                    | O                   |
| 6            | 006          | 2000            | O                    | O                   |
| 7            | 007          | 2000            | O                    | O                   |

(X = Died, O = Survived)

Dose Recommendation: The main test is complete.

Stopping criteria met: 3 at Limit Dose.

## SUMMARY OF LONG-TERM RESULTS:

| Dose<br>(mg/kg) | О | X | Total |  |
|-----------------|---|---|-------|--|
| 175             | 1 | 0 | 1     |  |
| 310             | 1 | 0 | 1     |  |
| 550             | 1 | 0 | 1     |  |
| 980             | 1 | 0 | 1     |  |
| 2000            | 3 | 0 | 3     |  |
| All Doses       | 7 | 0 | 7     |  |

Statistical Estimate based on long term outcomes: The LD50 is greater than 2000 mg/kg.



## ANNEXURE 2- DOSE PROGRESSIONS - OECD TG 425

| Slope = | 1    | 2    | 3    | 4    | 5    | 6    | 7    | 8     |
|---------|------|------|------|------|------|------|------|-------|
|         |      |      | 37.5 |      | •    | 37.5 |      | •     |
|         |      |      |      |      | 44   |      |      | 41    |
| *       |      |      |      |      |      |      | 47   |       |
|         |      | 55   |      | 55   |      | 55   |      | 55    |
|         |      |      |      |      |      |      | 65   |       |
|         |      |      |      |      | 69   |      |      | 73    |
|         |      |      | 81   |      |      | 82   |      |       |
|         |      |      |      | 99   |      |      | 91   | 97    |
|         |      |      |      |      | 109  | 120  |      |       |
|         |      |      |      |      |      |      | 126  | 129   |
|         | 175  | 175  | 175  | 175  | 175  | 175  | 175  | 175   |
|         |      |      |      |      | 277  | 262  | 240  | 230   |
|         |      |      |      |      | 275  | 260  |      |       |
|         |      |      | 275  | 310  |      | 275  | 340  | 310   |
|         |      |      | 375  |      | 440  | 375  |      | 410   |
|         |      |      |      |      | 440  |      | 470  | 410   |
|         |      | 550  |      | 550  |      | 550  | 470  | 550   |
|         |      | 550  |      | 330  |      | 250  | 650  | 330   |
|         |      |      |      |      | 690  |      | 030  | 730   |
|         |      |      | 810  |      |      | 820  |      | , , , |
|         |      |      |      | 990  |      |      | 910  | 970   |
|         |      |      |      |      | 1090 | 1200 |      |       |
|         |      |      |      |      |      |      | 1260 | 1290  |
|         | 1750 | 1750 | 1750 | 1750 | 1750 | 1750 | 1750 | 1750  |
|         |      |      |      |      |      |      | 2400 | 2300  |
|         |      |      |      |      | 2750 | 2600 |      |       |
|         |      |      |      | 3100 |      |      |      | 3100  |
|         |      |      |      |      |      | 3750 | 3400 |       |
|         |      |      |      |      |      |      |      | 4100  |
|         | 5000 | 5000 | 5000 | 5000 | 5000 | 5000 | 5000 | 5000  |



## ANNEXURE 3 - CERTIFICATE OF ANALYSIS L-3-AMINOISOBUTYRIC ACID



## Nanjing Nutrabuilding Bio-tech Co., Ltd.

## CERTIFICATE OF ANALYSIS

| Product Name L-3-Aminoisobutyric Acid |            |             |            |  |
|---------------------------------------|------------|-------------|------------|--|
| Batch No.                             | 20190801   | Quantity    | Sample     |  |
| Manufacturing Date                    | 2019.08.17 | Expiry Date | 2021.08.16 |  |

| Test Item                   | Specification                | Result                  | Method                  |
|-----------------------------|------------------------------|-------------------------|-------------------------|
| Physical and Chemical Exa   | mination                     |                         | •                       |
| Appearance                  | White crystalline powder     | Comforms                | Organoleptic            |
| Loss on Drying              | NMT 0.5%                     | 0.12%                   | USP<731>                |
| Assay (Dry Basis)           | NLT 98.0%                    | 99.64%                  | Titration               |
| D-3-Aminoisobutyric Acid    | NMT 1.0%                     | Not detected            | HPLC                    |
| Residue on Ignition         | NMT 0.2%                     | 0.04%                   | USP<281>                |
| Heavy Metals                | NMT 20 ppm                   | < 20 ppm                | ICP-MS                  |
| Arsenic (As)                | NMT 2.0 ppm                  | < 2.0 ppm               | ICP-MS                  |
| Lead (Pb)                   | NMT 2.0 ppm                  | < 2.0 ppm ·             | ICP-MS                  |
| Mercury (Hg)                | NMT 1.0 ppm                  | < 1.0 ppm               | ICP-MS                  |
| Cadmium (Cd)                | NMT 1.0 ppm                  | < 1.0 ppm               | ICP-MS                  |
| Microbiological Examination | MIN.                         |                         | •                       |
| Total Plate Count           | NMT 10000 cfu/g              | < 10000 cfu/g           | USP<61>                 |
| Yeast & Mold                | NMT 1000 cfu/g               | < 1000 cfu/g            | USP=61>                 |
| Coliform                    | NMT 10 mpn/g                 | < 10 mpn/g              | MPN                     |
| E.Coli                      | Negative in 10 g             | Negative                | USP=62>                 |
| Salmonella                  | Negative in 10 g             | Negative                | USP=62>                 |
| S.Aureus                    | Negative in 10 g             | Negative                | USP=:62>                |
| Others                      |                              |                         |                         |
| Storage Condition           | Stored in tightly sealed con | tainer, away from moist | ure and direct sunlight |
| Packing                     | Double PE bags in a net 25   | kg cardboard drum.      |                         |
| Shelf Life                  | 24 months from manufactu     | ring date.              |                         |
| Conclusion                  | Meet the Enterprise Standar  | rd.                     |                         |

Jiangsu Life Science and Technology Innovation Park, Xixia District, Nanjing, China 210046



## ANNEXURE 4 - CERTIFICATE OF ANALYSIS OF FEED

## **VRK Nutritional Solutions**

VRK's "Scientist's Choice" Laboratory Animal Feed 202, Ganga Celidium (Dhan Ganga Business Centre), Gangadham Phase - I, Blowewadi-Kondhwa Road, Pune - 411 037. India. Tel. : +91 20 2424 1169. E-mail : vrkgroup2009@gmail.com



## CERTIFICATE OF ANALYSIS

Name of the Product: Rat/Mice Pellet Feed

Description: A whitish brown colored pellets Pellet Size: 10-14 mm Solid Pellets Batch No: 023

Date of Mfg.: 13.08.2019 Date of Sampling: 14.08.2019 Date of Reporting: 14.08.2019 Date of Expiry :12.08.2020

Provimete analysis :

| No. | Test parameters | Detected values(in<br>percentage) | Standard values(in<br>percentage) |
|-----|-----------------|-----------------------------------|-----------------------------------|
| 1   | Moisture        | 8.48                              | 12 MAX                            |
| 2   | Crude Protein   | 18.25                             | 18 MIN                            |
| 3   | Crude Fat       | 3.54                              | 3 MIN                             |
| 4   | Crude fiber     | 5.40                              | 6 MAX                             |
| 5   | Calcium         | 1.20                              | 1 MIN                             |
| 6   | Phosphorus      | 0.54                              | 0.5 MIN                           |
| 7   | Total ash       | 6.00                              | 6 MAX                             |
| 8   | Carbohydrates   | 64.00                             | 60-65 MAX                         |
| 9   | Energy          | 3090 kcal/kg                      | 3000 kcal/kg MIN                  |

| 42 | MICLO | biological examination: |  |
|----|-------|-------------------------|--|
| 1  | No    | Test norometers         |  |

| No. | Test parameters        | Detected values | Standard values |
|-----|------------------------|-----------------|-----------------|
| 1   | Total Bacterial count  | 36 Cfu * /gm    | 1*10*           |
| 2   | Escherichia coli       | NIL**           | NIL             |
| 3   | Pseudomonas aeruginosa | NIL**           | NIL             |
| 4   | Staphylococcus aureus  | NIL**           | NIL             |
| 5   | Salmonella spp         | NIL**           | NIL             |
| 6   | Total mould count      | 00 Cfu * /gm    | 1-2             |
| 7   | Aflatoxin B1           | <10 ppb         | <10 ppb         |
| 8   | Aflatoxin B2           | <10 ppb         | <10 ppb         |
| 9   | Aflatoxin G1           | <10 ppb         | <10 ppb (       |
| 10  | Aflatoxin G2           | <10 ppb         | <10 ppb         |

<sup>\*</sup> cfu - colony forming unit.

Instructions: 1. Store the feed in cool, dry and well ventilated place off the floor.

Use within specified period.
 Stop usage of feed if found defective.

Solutions



<sup>\*\*</sup>Nil: Not detected in first dilution ( microorganisms below detectable limits)



## ANNEXURE 5 - CERTIFICATE OF ANALYSIS OF WATER



## TEST REPORT



ULR : TC504019000008482P

| Report No.<br>Sample Gode<br>e Date<br>tomor Ref.<br>Date | BALPL/19-20/GL-<br>27173807<br>10/06/2019<br>PO No. ERF/PO/1<br>27/07/2019 |                        |
|---|--|------------------------|
| of Registration   |  | 27/07/2019             |
| of commenceme   | ent of testing   | 27/07/2019             |
| of completion o   | ftesting   | 03/08/2/019            |
| sple Condition of   | receipt  | Found Ok<br>Amblent    |
| APLE TESTED AS  | RECEIVED   | -                      |
|   |  |                        |
|   | PLE TESTED A   | PLE TESTED AS RECEIVED |

| 1 C   | Test Parameters  Table 1 Organoleptic and Physologur  Idduir | VSIcal Paramet | 18:3025 (P.4)             | Requirement<br>(Acceptable<br>Limit) as per IS<br>10500:2012 | Pormissible Limit<br>in the absence of<br>alternate source<br>as por 15 10600:2012 | Result    |
|-------|--|----------------|---------------------------|--|--|-----------|
| 1 C   | colour   |                | 18:3025 (P.4)             | Is may   | T.:  |           |
| 2 0   | odour  | Hažen Units    |                           | 5 max  | 4.00   |           |
| _     |  | -              |                           | o man  | 15 mex   | <1        |
| -     | Ĥ  |                | 19:3026 (P.6)             | Agreeable  | Agrecable  | Agreeable |
| 3 pt  |  | -              | IS:3026 (P.11)            | 6.5 to 6.5   | No Relaxation  | 6.8       |
| 4 10  | 'asta'   | -              | IS:3025 (P.788)           | Agreesble  | Agreeable  | Agreeable |
| 5 T   | urbidity   | NTU            | IS:3026 (P.10)            | 1 max  | 5 max  | 1         |
| 6 To  | Total Dissolved Solids                                       | Nem            | 19:3025 (P.15)            | 500 mex  | 2000 max   | 49        |
| T     | Table 2 General Parameters C                                 | Concerning Su  | bstances Undestrable in E | xcessive emounts   |  |           |
| 7 A   | duminium as Al*  | mgñ.           | IS 3025 (P.2)             | 0.03 max   | 0,2 mex  | <0.01     |
| 8 1   | menonia (se total ammonia-N)                                 | mgA            | APHA 4500 NH3-F           | 0.5 max  | No relexation  | <0.06     |
| 9 1   | Vnionia Detergents as MBAS                                   | Ngm            | Annex K of IS 1342/1-2005 | 0.2 max  | 1.0 max  | <0.1      |
| 10 B  | Borlum qs Ba*  | mg/l           | 13 3025 (P.2)             | 0.7 mex  | No relexation  | <0.01     |
| 11 -B | Boron as B*  | mg/l           | IS 3025 (P.Z)             | 0.6 max  | 1.0 max  | <0.61     |
| 12 C  | Colidium as Co   | тол            | 13:3026 (P.40)            | 75 max   | 200 max  | 4.4       |
| 13 0  | Chloromines as CI2"  | mp0            | 19:3026 (P.26)            | 4.0 max  | No relaxation  | <0.1      |
| 14 G  | Chlorides at Cl  | img/l          | IS:3025 (P.32)            | 250 max  | 1000-max   | 13,2      |
| 15 C  | Copperate Cu*  | : mg/l         | IS 3025 (P.2)             | 0.05 max   | 1.5 mex  | <0.01     |
| 10 F  | Fluoride as F  | mg/l           | APHA 4500 F-D             | 1,0 mtsx   | 1.5 mex  | 1.02      |

Hymavethi Sonior chemist Authorized Signatory

Bhagavathi Ana Labs Pvt. Ltd. (A Bureau Veritas Group Company) Plot No. 7-2 C 7 & 874, Industrial Estate, Sunathnagar, Hyderabad 500 018 TELANGANA, INDIA TeL: +91 40 68144100 / 68144101





Study No. 190909/WGI/PC

## ANNEXURE 5 Continued



## TEST REPORT



|   |  | ŲL  | R: TC504019   | 000008482P          |
|---|--|---|---|---------------------|
|   |  | Fest Report No. Leb Sample Code Issue Date Customer Ref. Ref.Date | BALPU10-2000<br>27173807<br>10/08/2019<br>PO No. ERF/PO<br>27/07/2019 |                     |
| Sample Details  | RO Water   | Date of Registration  |   | 27/07/2018          |
|   |  | Date of commencement of testing                                   |   | 27/07/2019          |
|   |  | Sample Condition of receipt                                       |   | 03/08/2019          |
| Semple Collected By Mr. John Kenndy Gly. Received Sitr x 1no. and 1ltr x 1no. | Mr. John Kenndy  |   |   | Found Ok<br>Ambient |
|   | 5llr x 1no. and 1llr x 1no.                              |   |   |                     |
| Tests Required  | As per Quole . IND:BH.41.16.0677/FOC, Dated : 26/67/2019 |   |   |                     |


TEST RESULTS **Test Parameters** Pennissible Limit in the absence of Requirement (Acceptable

|      |   |               |                              | Limit) as per IS<br>10500:2012 | alternate source<br>as per IS 10500:2012 |        |
|------|---|---------------|------------------------------|--------------------------------|--|--------|
| 17   | Residual free chlorine, if<br>chlorinated | mg/li         | 18:3025 (P 26)               | 0.2 min                        | 1:0 min                                  | <0.01  |
| 1.0- | Iron as Fo <sup>a</sup>                   | mg/t          | 19.3025 (P.2)                | 0.3 max                        | No Reinxation                            | <0.01  |
| 19   | Magnesium sa Mg                           | img/li        | IS:3025 (P.46)               | 30'max                         | 100 max                                  | <1.    |
| 20   | Manganese as Mn*                          | mgri          | 15 3025 (P.2)                | 0.1 max                        | 0,3 max;                                 | <0.01  |
| 21   | Ministel Oil                              | mg/l          | 15:3025 (1 <sup>2</sup> .39) | 0.6 max                        | No Relaxation                            | <0,1   |
| 22   | Nitrate as NO3                            | hgm           | APHA 4600 NO3-B              | 45 mex                         | No Relexation                            | 138.1  |
| 23   | Phenalic Compounds as<br>C6H5OH           | mph.          | 15: 3025 (P.43)              | 0,001 max                      | 0.002 max                                | ×0.001 |
| 24   | Şelenlumi aş So*                          | . Ingn        | IS 3025 (P.2)                | 0.01 mpx                       | No Relexation                            | +0:01· |
| 25   | Silver as Ag*                             | mg/l          | IS 3025 (P.2).               | 0.1 mex                        | No Relaxation                            | <0.01  |
| 2,8  | Sulphete as 604                           | mon           | IS:3025 (P.24)               | 200 max                        | 400 max                                  | <1     |
| 27   | Sulphide as H2S                           | mg/t          | IS 9025 (P.29)               | 0.05 max                       | No Relexation                            | ×0.01  |
| 28   | Total Alkelinky CaCO3                     | Ngm           | IS:3025 (P.23)               | 200 mgx                        | 600 max                                  | 10,27  |
| 29   | Total Hardness as CaCO3                   | mg/l          | IS:3026 (P.21)               | 200 max                        | 600 max                                  | 13.2   |
| 30   | Zing as Zn'                               | mg/l          | 18 3025 (P.2)                | 5 max                          | 15 max                                   | 40.01  |
|      | Table 3 Parameters Conce                  | rning Toxic S | ubstances                    |                                |  |        |
| 31   | Cadmium as Cd+                            | mgri          | IS 3025 (P.2)                | 0.003 max                      | No relexation                            | <0.003 |
| 32   | Cyanide as CN                             | mg/l          | IS:3025 (P.27)               | 0.05 max                       | No relaxation                            | <0.1   |
| 33   | Load as Pb*                               | mgil          | IS 3025 (P.2)                | 0,01 max                       | No relexation                            | <0.01  |

Hymanathe comp Senior chemist Authorized Signatory

Bhagavathi Ana Labs Pvt. Ltd. GA Bureau Veritas Group Company)
Plot No. 7-2-C 7 & 8/4, Industrial Estate,
Sanathnagar, Flyderabad - 500 018.
TELANGANA, INDIA
Tel.: +91 40 68144100 / 68144101





## ANNEXURE 5 Continued



## TEST REPORT



NABL HY-001 ULR: TC504019000008482P

|                          |  | ULK: 10004019000008482P                                   |  |                     |  |
|--------------------------|--|---|--|---------------------|--|
|                          |  | Test Report No. Leb Sample Code Issue Date Clistbmer Ref. | 0ALPL/16:20/0<br>27173807<br>10/06/2019<br>PO No. ERF/PO |                     |  |
|                          |  | Ref.Date  | 27/07/2019   |                     |  |
| Sample Detpils           | RO Water                               | Date of Registration                                      |  | 27/07/2019          |  |
|                          |  | Date of commencement of testing                           |  | 27/07/2019          |  |
|                          |  | Date of completion of                                     | ftesting   | 03/08/2018          |  |
| Sample Collected By -    | Mr. John Konndy                        | Bample Condition of receipt                               |  | Found Ok<br>Ambient |  |
| Tests Required           | and the same a real                    |   | SAMPLE TESTED AS REGEIVED                                |                     |  |
| Sample collected england | millied by the representative of BALPL |   |  | Page No.            |  |
| Sample collected and sub | milled by the representative of BALPL  |   |  | Page                |  |

| 0.41  |                                      |       | TEST RES            |  |  |          |
|-------|--------------------------------------|-------|---------------------|--|--|----------|
| S,No. | Test Parameters                      | MOM   | Tent Mothod         | Requirement<br>(Acceptable<br>Limit) as per IS<br>10500:2012   | Permissible Limit<br>in the absonce of<br>elternate source<br>as per IS 10500:2012 | Rosuit   |
| 34    | Meroury as 150°                      | Nem   | 15 3025 (P.2)       | 0,001 mex  | No relaxation  | <0.001   |
| 35    | Molybelonum on Mo*                   | mgri  | 13 3026 (P.2)       | 0.07 max   | No relexation  | F0.02    |
| 30    | Michal as Mi*                        | mg/l  | 18 3026 (P.2)       | 0.02 max   | No relaxation  | 40.01    |
| 37    | Physiochlorinoleid biphenyls         | mgs   | Annex M of IS 13428 | 0.0006 max   | No relaxation  | <0.00001 |
| 50    | Polynicicar Aromatic<br>hydrocarbons | mgri  | APHA 6440           | 0.0001 max   | No retaxetion  | ≺0.00001 |
| 200   | Total Arsenic as As*                 | mgd   | IS 3025 (P.2)       | 0.01 max   | 9.05 max   | <0.01    |
| 40    | Total Chromium as Cr*                | mgit  | 18 3025 (P.2)       | 0.05 mgx   | No relaxation  | <0.01    |
|       | Trihalomothenes                      |       |                     | The state of the s | THO TERMOODES  | <0.01    |
| 41    | Gramatorm                            | mg/l  | EPA 524.3           | 0,1 max  | No retaxition  | <0.0005  |
| 42    | Dibromochloromethane                 | mgit  | EPA 524,3           | 0.1 max  | No relaxation  | <0.0005  |
| 43    | Bromodichloromethane                 | non   | EPA 524.3           | 0.05 mex   | No relaxation  | <0.0005  |
| 44    | Chloroform                           | mg/t  | EPA 024.3           | 0.2 max  | No relaxation  |          |
|       | Table 5. Pesticide Residues          |       | 1-1.1-1.1           | V.2.1104   | INO regulation   | ≺0,0003  |
|       | Aldrin & Dieldrin                    | NBu   | USEPA 508           | 0.03 max   | Т  | Tienes   |
| 46    | 0,p- 00T                             | Γρομ  | USEPA 508           | 1 max  | <u></u>  | <0.01    |
| 47    | p.p - DDT                            | POU   | USEPA 508           |  |  | <0,01    |
| 40    | a.p. DDE.                            |       | USEPA 508           | 1 max  | -  | <0.01    |
| _     | p,8 - DDE                            | feet  | F                   | 1 max  | 1  | <0.01    |
|       |                                      | 119ri | USEPA BOB           | 1 max  |  | < 0.01   |

Hymevathi Senior chemiat Authorized Signatory



Bhagavathi Ana Labs Pvt. Ltd. (A Bureau Veritas Group Company) Plot No. 7.2-C.7 & 874. Industrial Estate. Sanathongar. Hyderabad - 500 018 TELANCANA, INDIA Tel.: +01 40 68144100 / 68144101





## **ANNEXURE 5 Continued**



## TEST REPORT



NABL.HY-001 ULR: TC504019000008482P

|                         |   | Test Report No. Lab Sample Code has Date Customer Ref. Ref.Date  | BALPL/19-20/0<br>27173807<br>10/08/2019<br>PO No. ERF/PI<br>27/07/2019 |                     |  |
|-------------------------|---|--|--|---------------------|--|
| Sample Details          | RO Water  | Date of Registration   |  | 27/07/2019          |  |
|                         |   | Date of commencement of testing<br>Date of completion of testing |  | 27/07/2010          |  |
|                         |   |  |  | 03/06/2019          |  |
| Sample Collected By     | Mr. John Kenndy   | Sample Condition of  | robolpt  | Found Ok<br>Amblent |  |
| Qty. Received           | ty. Received 5ltr x 1no. and 1ltr x 1no.                  |  | SAMPLE TESTED AS RECEIVED  |                     |  |
| Yosts Required          | As per Quote : IND.BH 41.18.0577/FOG, Disted : 25/07/2019 |  |  |                     |  |
| Sample collected and su | omitted by the representative of BALPL                    |  |  | Page No. 4          |  |

|       |  |        | TEST RES    | ULTS   |  |        |
|-------|--|--------|-------------|--|--|--------|
| 5.No. | Test Paramotera                                      | UOM    | Yest Method | Requirement<br>(Acceptable<br>Limit) as per is<br>10500:2012 | Permissible Limit<br>in the absence of<br>alternate source<br>as per i3 10500:2012 | Result |
| 60    | o.p- DDD   | HOM    | UBEPA 800   | 1 max  | -  | ≺0:01  |
| .51   | jx,p - DOD   | рди    | USEPA.508   | 1 mex  | -  | <0.01  |
| 52    | Lindane  | PDA    | USEPA 508   | 2 max  | -  | <0.01  |
| 53    | Endosulfen (sum of isomers &<br>Endosulfen autohato) | hBy    | USEPA 608   | 0.4 max  |  | <0.01  |
| 54    | Alpha-HCH.   | μοη    | USILPA: 508 | 0,01 max   |  | ≪0.01  |
| 55    | Bata-HCH   | hou    | USEPA 808   | 0.04 max   | -  | <0.01  |
| 56    | Delta-HCH  | hgri   | USEPA 608   | 0,04 max   | * .  | <0.01  |
| 57    | Mothyl Parathion                                     | Pgu    | USEPA 8141A | 0.3 max  | -  | <0,01  |
| 58    | Aladalor   | signi. | USEPA 525.2 | 20 max   |  | <0.01  |
| 89    | Atrazine   | , por  | USEPA'8141A | 2 mox  | 10   | <0.01  |
| 60    | Butachfor  | hay    | USEPA 8141A | 125 max  |  | <0:01  |
| 61    | Chiorpyrtios   | PSA    | USEPA 8141A | 30 mihx.   |  | <0.01  |
| 62    | Elhion   | 105    | USEPA 1897A | 3 inax   | -  | <0.01  |
| 63    | Isoproturon  | Иди    | USEPA 532   | 9 max  | -  | <0.01  |
| 64    | Malathian  | pon.   | USEPA 8141A | 190 mex  | -  | <0.01  |
| 65    | Monocrolophos  | Paul   | USEPA 8141A | 1 max  |  | ±0,01  |
| 88    | Phoreto  | 210/1  | USEPA 8141A | 2 max  | •  | <0.01  |
| 67    | 2,4-D  | Ngq    | USEPA 615.1 | 30 max   | -  | <0.01  |
|       |  |        |             |  |  |        |

Aymavathi Senior chemist Authorized Signatory

Bhagayathi Ana Labs Pyt. Ltd. (A Bureau Veritas Group Company) Piot No. 7-2-C 7 & 8/4, Industrial Estate, Sanathnagar, Hyderabad - 500 018. TELANGANA, INDIA TEL: +91 40 68144100 / 68144101



Authorized Photo copy (Sigh & Date)

## **ANNEXURE 5 Continued**



## TEST REPORT



|   |  | U   | LR: TC504019   | 000008482P          |
|---|--|---|--|---------------------|
| 4   |  | Test Report No. List Sample Code Issue Date Customer Ref. | 8ALPL/19-20/0<br>27173807<br>10/08/2019<br>PO No. ERF/PC   |                     |
| Sample Details  | FIQ Water  | Rof,Date  | 27/07/2019   |                     |
| po Decima   | RIO Water  | Date of Registration                                      |  | 27/07/2019          |
|   |  | Date of commenceme  | ent of testing   | 27/07/2019          |
|   |  | Date of completion of                                     | festing  | 03/06/2019          |
| Sample Collected By Mr. John Kenndy<br>Ity. Roceived Silic x Inc. |  | Sample Condition of receipt                               |  | Found Ok<br>Ambient |
|   |  | SAMPLE TESTED AS RECEIVED                                 |  |                     |
| Tests Required  | As per Quote : INO.BH.41.18.0577/FOC, Dated . 28/07/2019 |   | in the second se |                     |
| Sample collected and au   | briftled by the representative of BALPL                  |   |  | Page No. 5/         |

|       |   |               | TEST RES      | ULTS   |  |        |
|-------|---|---------------|---------------|--|--|--------|
| S.No. | Test Parkmotors   | DOW           | Test Method   | Requirement<br>(Acceptable<br>Limit) as pir 15<br>10500:2012 | Pormissible Limit<br>in the absence of<br>alternate source<br>as per IS 10100:2012 | Result |
|       | Table 6 Bacterial Quality of C                                    | Orinking Wate | f             |  |  |        |
| 1     | Thtal Collorn becterla  | per 100mi     | IS 18185:2010 | Shall not be<br>detectable in any<br>100ml of santale        |  | Absort |
|       | E.coll or thermotolegant cultorin<br>Soctoria (Faecal Colliforms) | per 100ml     | IS 15185;2010 | Sholl not be<br>detectable in any<br>100ml of sample         | F  | Absent |

Romarks: (1) The submitted sumple complies to its 16500-2012 water for Drinking purpose with respect to above tested personeters.

\*marked pleasheders are not covered oncer NABL Scope.

Bhagavathi Ana Labs Pvt. Ltd. A Buresu Verius Group Company)
Plot No. 7-2-C 7 & 8/4, Industrial Estate,
Sanathnagas, Hyderabad - 500 018.
TELANGANA, INDYA
Tel.: +91 40 68144100 / 68144101




Authorized Signatory





## ANNEXURE 6 - CERTIFICATE OF ANALYSIS OF BEDDING MATERIAL



Opposite Sadhana Petroi Pump, Kolhapur Road, Sangli - 416 416 Maharashtra (Bharat)

• Email:nikhli\_lab@yahoo.com • Phone:+919552574418

## CERTIFICATE OF ANALYSIS

| Name/ C<br>Sample | rganization<br>Description   | VRK Nutritional Solution | ne, MIDC Mirej.              | <br>04/09/2019           |
|-------------------|--|--------------------------|------------------------------|--------------------------|
| Sample<br>Sample  | Sample Collected by Party Sample Analysed by Smt. Alshwarya Tolerence Batch No. 015, N |                          | Sample Receive Apalysis Comp | 20/08/2019<br>04/09/2019 |
| Sr.               | Parameter  |                          | Unit                         | <br>ntuo                 |
| A.                | Aflatoxina   |                          |                              | <br>8100                 |

| Affatoxing   Affatoxing   | Sr. | Parameter               | Unit   | Vatuo  |  |  |
|---|-----|-------------------------|--|--|--|--|
| Allutoxin G2  | A.  | Aflatoxins              | 4.11   | Value  |  |  |
| Allatoxin G2  | 1.  | Allatexin G1            | pob  | 510  |  |  |
| Milatoxin B1  | 2.  | Aflatoxin G2            |  |  |  |  |
| Affaltoxin B2   | Э.  | Aflatoxin B1            |  |  |  |  |
| Pesticide Realduces   2, 4 UDE   2, 6 UDE | 4.  | Affatoxin B2            |  |  |  |  |
| 4, 4 DDE ppb <0.01  4, 4 DDT ppb <0.01  4, 4 DDT ppb <0.01  Alpha HCH ppb <0.01  Hela HCH ppb <0.01  Delta HCH ppb <0.01  Total Bacterial Count clu/g 15 X 10 <sup>3</sup> Total Fungal Count clu/g 17 X 10 <sup>3</sup> Escherich/s coli clu/g 17 X 10 <sup>3</sup> Escherich/s coli clu/g Absent  | B.  | Pesticide Residues      | pp.  | C10  |  |  |
| 4, 4 DDE  | 1.  | 2, 4 ODE                | pob T  | -0.01  |  |  |
| 4, 4 ODD  | 2.  |                         |  |  |  |  |
| 4 4 DDT   | 3.  | 4, 4 DDD                |  | The second secon |  |  |
| Alpha HCH   | 4.  | 4, 4 DDT                |  | and the second s |  |  |
| Hela HCl  | 5.  | Alpha HCH               | The second second second   | The state of the s |  |  |
| Delta HCH   | G.  | Bela HCH                |  |  |  |  |
| Delicin   | 7.  | Delta HCH               |  |  |  |  |
| Lindano   ppb   <0.01   | 41. | Dieldrin                | The second secon |  |  |  |
| Matabilion   ppb   <0.10  | 9   | Lindano                 |  |  |  |  |
| Microbiological Analysis   Total Becterial Count   clu/g   15 X 10 <sup>3</sup>   Total Fungal Count   clu/g   17 X 10 <sup>1</sup>   Escherichia coli   clu/g   Absent   | 0.  | Malathion               |  |  |  |  |
| Total Sactorial Count   clu/g   15 X 10 <sup>2</sup>   Total Fungal Count   clu/g   17 X 10 <sup>1</sup>   Total Fungal Count   clu/g   17 X 10 <sup>1</sup>   Eacherichia coli   clu/o   Absent  | -   |                         |  |  |  |  |
| Total Fungal Count clulg 17 X 101  Escherichia coli ctulo Absent  | 1.  |                         | clufa  | 15 V 103   |  |  |
| Escherichia coli clufo Absent   | 2.  |                         |  |  |  |  |
|   | 3.  | Escherichia coli        |  |  |  |  |
| Salmonella Spp. clu/g Absent  | 4,  | Salmonella Spp.         |  |  |  |  |
| Staphylococcus aureus olu/g Absent  | 5.  |                         |  |  |  |  |
| 7 Date 11   | B   |                         |  |  |  |  |
| Pseudomonas aeruginosa clu/g Absent   |     | Pseudornonas aeruginosa | cfu/g  | Absent   |  |  |

Authorized Photo copy 3.55 (A) & Dato)

4 Ale Analyst / Lab In-Charge Managing Director Nikhil Suhas Khambe

B Tech (Bio-leich)

Call Co

Note: The region can not be used for court purpose, we are not responsible for any legal matter.

FOUR FEED, WATER, SOIL, PLANT MATERIAL, ORGANIC MANURE, CHEMICAL-BIOLOGICAL FERTILIZER, PGR, AYURVEDIC & PHARMACEUTICALS, INDUSTRIAL MATERIAL, SOLID WASH.

WASTE WATER, AIR POLLUTION, ENVIRONMENTAL MONHORING & ETP CONSTRUCTION.

AGMARK Approved No 0-stockerzossetab From Ministry of Agricultum, Department of Marketing & inspection, Guy, of India & State Govt.

Approved for Sod & Water Analysis (SNG/STLR No. 1207/2012), Approved for Fortilizor Testing.